SARS-CoV-2 challenge studies: ethics and risk minimisation

COVID-19 poses an exceptional threat to global public health and well-being. Recognition of the need to develop effective vaccines at unprecedented speed has led to calls to accelerate research pathways ethically, including by conducting challenge studies (also known as controlled human infection st...

Full description

Saved in:  
Bibliographic Details
Authors: Bull, Susan (Author) ; Jamrozik, Euzebiusz (Author) ; Binik, Ariella (Author) ; Parker, J. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2021
In: Journal of medical ethics
Year: 2021, Volume: 47, Issue: 12
Online Access: Volltext (kostenfrei)
Volltext (kostenfrei)

MARC

LEADER 00000caa a22000002 4500
001 1816167185
003 DE-627
005 20230426125631.0
007 cr uuu---uuuuu
008 220908s2021 xx |||||o 00| ||eng c
024 7 |a 10.1136/medethics-2020-106504  |2 doi 
035 |a (DE-627)1816167185 
035 |a (DE-599)KXP1816167185 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Bull, Susan  |e VerfasserIn  |4 aut 
245 1 0 |a SARS-CoV-2 challenge studies: ethics and risk minimisation 
264 1 |c 2021 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a COVID-19 poses an exceptional threat to global public health and well-being. Recognition of the need to develop effective vaccines at unprecedented speed has led to calls to accelerate research pathways ethically, including by conducting challenge studies (also known as controlled human infection studies (CHIs)) with SARS-CoV-2 (the virus which causes COVID-19). Such research is controversial, with concerns being raised about the social, legal, ethical and clinical implications of infecting healthy volunteers with SARS-CoV-2 for research purposes. Systematic risk evaluations are critical to inform assessments of the ethics of any proposed SARS-CoV-2 CHIs. Such evaluations will necessarily take place within a rapidly changing and at times contested epidemiological landscape, in which differing criteria for the ethical acceptability of research risks have been proposed. This paper critically reviews two such criteria and evaluates whether the use of effective treatment should be a necessary condition for the ethical acceptability of SARS-CoV-2 CHIs, and whether the choice of study sites should be influenced by COVID-19 incidence levels. The paper concludes that ethical evaluations of proposed SARS-CoV-2 CHIs should be informed by rigorous, consultative and holistic approaches to systematic risk assessment.There are no data in this work. 
601 |a SARS-CoV-2 
601 |a Challenger 
700 1 |a Jamrozik, Euzebiusz  |e VerfasserIn  |4 aut 
700 1 |a Binik, Ariella  |e VerfasserIn  |4 aut 
700 1 |a Parker, J.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 47(2021), 12, Artikel-ID 79  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:47  |g year:2021  |g number:12  |g elocationid:79 
856 |u https://jme.bmj.com/content/medethics/47/12/e79.full.pdf  |x unpaywall  |z Vermutlich kostenfreier Zugang  |h publisher [open (via page says license)] 
856 4 0 |u https://doi.org/10.1136/medethics-2020-106504  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/47/12/e79.abstract  |x Verlag  |z kostenfrei  |3 Volltext 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4185621132 
LOK |0 003 DE-627 
LOK |0 004 1816167185 
LOK |0 005 20220908053816 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-03#996F6EEEBBF27F4DB604D8B4C00938BE6C6A7296 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1 
ORI |a SA-MARC-ixtheoa001.raw